News List

Holiday Notice of Dragon Boat Festival
2019-06-01

To all departments and employees:According to the related national legal & the actual situation of our company, we i

Long-term anti-AIDS, Combination of two schemes submits application
2019-05-29

On April 29, 2019,the anti-AIDS long-acting two-party “cabotegravir + Ripirilin”submitted to the FDA for listing applica

For the initial treatment of HIV patients, the FDA approved the first dual-agent combination therapy
2019-04-27

Today, the US FDA announced that it has approved the listing of the antiviral therapy Dovato (dolutegravir and lamivudin

Novartis‘s Multiple sclerosis Innovative drug approved
2019-03-29

Recently, US FDA announced approved the listing of Mayzent (siponimod) developed by Novartis, for the treatment of recur

Highly efficient trifluoromethylation and [18F]trifluoromethylation
2019-03-02

Jichang Xiao, researcher at Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, has created a new trif

Redox neutral [4+1] cyclic reaction based on C-F fracture
2019-01-19

Recently, Professor Feng Chao of the Institute of Advanced Synthesis of Nanjing University of Technology and Professor R

FDA accelerates approval of no-limit cancer targeting therapy for the treatment of NTRK fusion tumors
2018-12-15

Recently, LOXO Oncology and Bayer jointly announced that the FDA has accelerated the approval of a co-developed VITRAKVI

FDA approves new mechanism for listing new anti-influenza drugs
2018-11-17

Today, the US FDA announced the approval of the new anti-influenza drug Xofluza (baloxavir marboxil), jointly developed

FDA grants Relacorilant the qualification for orphan drugs for pancreatic cancer
2018-10-20

Pancreatic cancer is the fourth leading cause of cancer-related deaths with a 5-year survival rate of 5%. In the United

For the first time, scientists have discovered fluorine in natural conditions
2018-09-20

Fluorine is the most reactive chemical element. That is why it is not found in nature in its elemental form, but only in